Skinny Labels and Section VIII Carve-Outs: A Generic Entry Strategy

Section viii carve-outs allow generic drug companies to launch products before all Orange Book patents expire by omitting still-patented indications from their labeling. This strategy is a powerful but legally nuanced tool for accelerating generic entry.

What Is Section viii?

Section viii refers to the provision in 21 CFR 314.94(a)(12)(iii)(A) that allows an ANDA applicant to omit information about patented methods of use from its proposed labeling. When a brand-name drug has multiple approved indications and some of those indications are protected by method-of-use patents, a generic applicant may file an ANDA that covers only the unpatented indications. This is known as a “Section viii statement” or “Section viii carve-out.”

The legal basis is straightforward: if a generic does not seek approval for a patented indication, it does not need to certify to the patent covering that indication. This avoids triggering Paragraph IV litigation on those specific method-of-use patents, potentially allowing the generic to reach the market years earlier than if it had to challenge every listed patent.

How Skinny Labels Work

A “skinny label” is the colloquial term for a generic drug's FDA-approved labeling that omits one or more indications present on the brand-name reference listed drug (RLD) label. The process works as follows:

1. The generic applicant identifies which indications on the RLD label are protected by method-of-use patents listed in the Orange Book.
2. The ANDA is filed with proposed labeling that includes only the indications not covered by those patents, along with a Section viii statement for the omitted, patented indications.
3. The FDA reviews and may approve the ANDA with the narrower label, provided the generic is bioequivalent to the RLD and the remaining indications are adequately supported.
4. The generic launches with its skinny label. Pharmacists in most states can substitute the skinny-label generic for prescriptions written for any indication of the brand product, because state substitution laws are based on therapeutic equivalence ratings, not indication-specific labeling.

Patent Type Classification Matters

The viability of a Section viii carve-out depends entirely on how the remaining Orange Book patents are classified:

• Compound (drug substance) patents: Cannot be carved out. If a compound patent is in force, no generic version of that compound can be marketed regardless of indication.
• Formulation (drug product) patents: Cannot be carved out. The generic must certify to these patents (typically Paragraph IV) or wait for expiration.
• Method-of-use patents: These are the only patents eligible for Section viii carve-outs. If the only remaining unexpired patents are method-of-use patents, a generic can potentially launch with a skinny label omitting those indications.

When Carve-Outs Are Most Valuable

Section viii carve-outs create the most significant commercial opportunities when method-of-use patents expire substantially later than compound and formulation patents. The classic scenario is:

• A brand drug's compound patent expires, eliminating the broadest protection.
• The drug has no remaining formulation patents (or those have also expired).
• One or more method-of-use patents remain in force, covering later-approved indications (e.g., new therapeutic uses discovered after initial approval).
• The remaining patented indications represent a minority of actual prescribing volume, meaning the skinny label captures most real-world utilization.

In this scenario, a generic company can launch years before the final method-of-use patent expires, capturing significant market share for the unpatented indications while technically avoiding infringement.

Risks and Limitations

Despite its appeal, the Section viii carve-out strategy carries meaningful risks:

Induced Infringement Claims

Brand companies may argue that even a skinny-label generic induces infringement of method-of-use patents because physicians prescribe for patented indications regardless of what the generic label says. The Federal Circuit's decision in GSK v. Teva (carvedilol) established that a generic company can be liable for induced infringement if it knows its product will be used for a patented indication, even with a carved-out label.

State Substitution Laws

In most states, pharmacists are required or permitted to substitute a therapeutically equivalent generic regardless of the specific indication prescribed. This means a skinny-label generic will inevitably be dispensed for patented indications, creating potential infringement exposure for the generic manufacturer.

Prescriber Behavior

Physicians typically prescribe by drug name, not indication. A prescription for “carvedilol” may be for heart failure (the patented indication in the historical carvedilol case) or hypertension (the unpatented indication). The generic company has no practical way to control which indication drives each prescription.

Notable Section viii Cases

Carvedilol (COREG)

The carvedilol case is the most significant Section viii precedent. GlaxoSmithKline's COREG was approved for hypertension and later for heart failure, with method-of-use patents covering the heart failure indication. Teva launched a skinny-label generic omitting the heart failure indication. GSK sued for induced infringement, and the Federal Circuit held that Teva could be liable because its label and marketing materials effectively encouraged use for the patented indication. The case established that a skinny label alone does not provide complete protection from infringement claims.

Omeprazole (PRILOSEC)

AstraZeneca's PRILOSEC (omeprazole) presented another landmark skinny label scenario. Generic omeprazole launched with labeling that omitted certain patented uses while retaining the core acid-reduction indications. The case highlighted the commercial viability of carve-outs when the unpatented indications represent the vast majority of prescribing volume.

How LOERadar Identifies Carve-Out Opportunities

LOERadar analyzes the Orange Book to automatically identify drugs where Section viii carve-outs may be viable. The platform examines:

• Patent type classification for every listed patent (compound, formulation, method-of-use)
• Relative expiration dates to detect gaps between compound/formulation patent expiry and method-of-use patent expiry
• Existing Paragraph IV certifications and ANDA activity that may signal generic interest
• Litigation history for prior Section viii challenges on the same drug

Skinny label opportunity analysis tools are coming soon to the Intelligence hub.

Continue Learning

Disclaimer: This content is for educational purposes only and does not constitute legal advice. Section viii carve-out strategies involve significant legal risk and should be evaluated with qualified patent counsel before pursuit.